BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and immuno-modulatory antibodies for cancer therapy. The company is headquartered in Lund, Skane and currently employs 122 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Follow-Up Questions
What is the price performance of BOVNF stock?
The current price of BOVNF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for BioInvent International AB?
BioInvent International AB belongs to Biotechnology industry and the sector is Health Care
What is BioInvent International AB market cap?
BioInvent International AB's current market cap is $0
Is BioInvent International AB a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for BioInvent International AB, including 3 strong buy, 5 buy, 1 hold, 0 sell, and 3 strong sell
